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Abstract
Background: HOX genes encode a family of homeodomain-containing transcription factors involved in the
determination of cell fate and identity during embryonic development. They also behave as oncogenes in some
malignancies.
Results: In this study, we found high expression of the HOXD9 gene transcript in glioma cell lines and human
glioma tissues by quantitative real-time PCR. Using immunohistochemistry, we observed HOXD9 protein expression
in human brain tumor tissues, including astrocytomas and glioblastomas. To investigate the role of HOXD9 in
gliomas, we silenced its expression in the glioma cell line U87 using HOXD9-specific siRNA, and observed
decreased cell proliferation, cell cycle arrest, and induction of apoptosis. It was suggested that HOXD9 contributes
to both cell proliferation and/or cell survival. The HOXD9 gene was highly expressed in a side population (SP) of
SK-MG-1 cells that was previously identified as an enriched-cell fraction of glioma cancer stem-like cells. HOXD9
siRNA treatment of SK-MG-1 SP cells resulted in reduced cell proliferation. Finally, we cultured human glioma
cancer stem cells (GCSCs) from patient specimens found with high expression of HOXD9 in GCSCs compared with
normal astrocyte cells and neural stem/progenitor cells (NSPCs).
Conclusions: Our results suggest that HOXD9 may be a novel marker of GCSCs and cell proliferation and/or
survival factor in gliomas and glioma cancer stem-like cells, and a potential therapeutic target.
Background
Gliomas, especially glioblastomas (GBMs), are the most
malignant primary brain tumors[1]. The median survival
of a patient with GBMs is 15 months, and this has
improved little by temozolomide treatment[2]. GBMs
have a high rate of cellular proliferation and a marked
propensity to invade remote brain structures. Such
aggressive and invasive growth is the hallmark feature
that gives rise to their high morbidity and mortality. A
better understanding of the mechanisms underlying the
initiation and progression of GBMs at the molecular
and cellular levels will open up new opportunities to
develop therapeutic strategies.
The growth of many tumors depends on a subset of
tumor cells with an extensive capacity for self-renewal,
called either cancer stem cells (CSCs) or tumor-initiat-
ing cells[3]. Several studies report the presence of CSCs
in gliomas[4,5]. In glioma CSC (GCSC), the expression
of some neural stem markers, such as SOX2 and Musa-
shi-1, has been reported[6,7]. In addition, some markers
including CD133[8] and SSEA-1 (CD15)[9] have been
evaluated as GCSC enrichment markers; however, sev-
eral studies show their limitations as specific markers
[10,11].
Homeobox proteins are master regulators of develop-
ment and control many cellular processes, including
proliferation, apoptosis, cells h a p e ,a n dc e l lm i g r a t i o n .
Homeobox proteins belong to a superfamily, and are
encoded by a number of genes, such as SIX, MSX, PAX,
LIM,a n dHOX[12]. Among Homeobox proteins, HOX
genes encode transcription factors that act as critical
regulators of growth and differentiation, control of cell
identity, cellular communication, cell cycle progression,
hematopoiesis, and apoptosis in addition to the control
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HOX genes have been identified and partly or fully
redundant functions of HOX genes have also been
known[13].
HOX genes have been reported to be misexpressed in
many tumors including lung carcinoma, neuroblastoma,
ovarian carcinoma, cervical carcinoma, prostate carci-
noma, breast carcinoma, and leukaemia[14]. In addition,
epigenetic control of HOX genes in development and
diseases have been shown in many studies[15]. In a pre-
vious study, we performed restriction landmark genomic
scanning (RLGS) with a CpG methylation-sensitive
enzyme to identify CpG islands of genes that are differ-
entially methylated in human glioma cells compared
with normal lymphocytes to find epigenetically con-
trolled genes in glioma[16], and identified 12 genes that
seem to be regulated by epigenetic gene modification.
One of the identified genes was HOXD9[16]. HOXD9 is
critical for embryonic segmentation[17] and limb bud
patterning[18] during development, but its biological
function in human adult tissues has been elusive.
Recently, it was reported that HOXD genes were
expressed in neoplastic astrocytes[19] and pediatric low-
grade gliomas[20]. However much less is known about
the function of HOXD genes especially in gliomas. In
this study, we analyzed the expression and function of
HOXD9 in human gliomas and found high expression of
HOXD9 in GCSCs. HOXD9 contributes to cell prolifera-
tion and/or survival in glioma cells and glioma cancer
stem-like cells. Thus, HOXD9 may be a new target for
the treatment of gliomas based on GCSC population.
Methods
Tissue samples and cell lines
All tumor tissue specimens were obtained from patients
with glioma who underwent surgery at the Department
of Neurosurgery, Keio University School of Medicine
and the Department of Neurosurgery, Sainte Anne Hos-
pital, Medical School of Paris Descartes University.
Tumors obtained from surgical cases were classified
according to the World Health Organization (WHO)
criteria[21] as follows: glioblastoma (WHO grade IV),
anaplastic astrocytoma (WHO grade III), or diffuse
astrocytoma (WHO grade II). Written informed consent
was obtained from all patients in the study, which was
conducted in accordance with the Institutional Review
Board guidelines of Keio University or Paris Descartes
University. Human glioma cell lines (U87, SK-MG-1,
KNS42, KNS81) were obtained from the American Type
Culture Collection (Manassas, VA) and the Japanese
Collection of Research Bioresources (Osaka, Japan), and
maintained in Dulbecco’s modified Eagle’sm e d i u m
(Wako, Tokyo, Japan) supplemented with 10% fetal
bovine serum (FBS) and antibiotics (50 IU/ml benzyl
penicillin G potassium and 100 μg/ml streptomycin sul-
fate; Meiji, Tokyo, Japan). Side population (SP) and non-
SP SK-MG-1 cells were isolated using a flow cytometer
(EPIC Altra; Beckman Coulter, Tokyo, Japan) as pre-
viously described[22]. Human neural stem/progenitor
cells (NSPCs) were cultured as neurospheres (NSPs) in
neurosphere culture medium consisting of Neurobasal
Medium (Invitrogen, Carlsbad, CA) supplemented with
human recombinant (hr) EGF (20 ng/mL; Peprotech,
Rocky Hills, NY), hrFGF2 (10 ng/mL; Peprotech), hrLIF
(10 ng/mL; Millipore-Japan, Tokyo, Japan), heparin (5
μg/ml; Sigma, St. Louis, MO) and B27 (Invitrogen) as
previously described[23]. Primary astrocyte cells were
purchased from Takara Bio (Tokyo, Japan). GCSC lines
were established from human glioma tissue specimens
as described in a previous study[10].
RNA extraction and quantitative (q) RT-PCR
Total RNA was isolated from human glioma tissues and
cell lines using Trizol (Invitrogen). Total RNA from nor-
mal tissues was purchased from Clontech (Palo Alto,
CA). Synthesis of cDNA was performed using 1 μgo f
total RNA using Reverse transcriptase XL (AMV) or Pri-
meScript RT Master Mix (Takara Bio). The primers
were designed as follows: for HOXD9,f o r w a r dp r i m e r ,
5’-GAGGAGGAGAAGCAGCATTC-3’, reverse primer,
5’-TTCTCCAGCTCAAGCGTCTG-3’;f o rSOX2,f o r -
ward primer, 5’-ATGGACAGTTACGCGCACA-3’,
reverse primer, 5’-TGCGAGTAGGACATGCTGTA-3’;
for BCL-2,f o r w a r dp r i m e r ,5 ’-AGGATTGTGGCC-
TTCTTTGAGT-3’, reverse primer, 5’-GCCGGTTCA-
GGTACTCAGTCAT-3’;f o rTRAIL forward primer, 5’-
CGTGTACTTTACCAACGAGCTGA-3’, reverse primer,
5’-ACGGAGTTGCCACTTGACTTG-3’;a n df o r
GAPDH,f o r w a r dp r i m e r ,5 ’-TGAACGGGAAGCT-
CACTGG-3’, reverse primer, 5’-TCCACCACCTGTTG-
CTGTA-3’. We designed intron-spanning primers to
amplify HOXD9 and SOX2.F o rBCL-2 and TRAIL,
respectively, previously tested and optimized primer sets
were used as described in Brown (2007)[24] and Wil-
liams (2003) [25]. Quantitative RT-PCR analysis was
performed with a fluorescent dye, SYBR Green (Applied
Biosystems, Foster City, CA), using the ABI prism 7900
HT Sequence Detection System (Applied Biosystems) as
previously described[23]. The PCR parameters were as
follows: 10 min at 95°C, then 40 cycles of denaturation
at 95°C for 1 min, annealing at 60°C for 1 min, and
extension at 72°C for 1 min. The relative gene expres-
sion level was normalized to that of GAPDH in each
sample and calculated as the threshold cycle (CT) value
in each sample divided by the CT value in each refer-
ence. The CT value is defined as the value obtained in
the PCR cycle when the fluorescence signal increases
above the background threshold.
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Approximately 10
6 U87 cells were used for total RNA
extraction using the RNeasy mini kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. RNA
quality was verified with the Bioanalyzer System (Agilent
Technologies, Palo Alto, CA) using RNA Nano Chips.
RNA (1.5 μg) was processed for hybridization on the
Genechip Human Genome U133 Plus 2.0 Expression
array (Affymetrix, Santa Clara, CA), which contains over
54,000 probe sets for analyzing the expression level of
over 47,000 transcripts and variants, including 38,500
well-characterized human genes. Processing was done
according to the manufacturer’s recommendations.
Except when indicated, all genomic and transcript analy-
sis was carried out using GeneSpring software 7.3.1
(Agilent Technologies). Microarray data were deposited
at the NCBI Gene Expression Omnibus (GEO:
GSE28618).
GEO data sets (http://www.ncbi.nlm.nih.gov/gds/)
were used to analyze mRNA expression microarray data
from several brain tumors and normal brain. The fol-
lowing samples were subjected to analysis: normal brain
(65 normal human brain tissue samples from ten post-
mortem donors, Roth et al., 2006[26], GSE3526); medul-
loblastoma (62 samples, Kool et al., 2008[27],
GSE10327); oligodendroglioma grade II and III, astrocy-
toma grade II and III, and glioblastoma grade IV (157
samples, Sun L et al., 2006[28], GDS1962). Comparisons
were made using the method of Kool et al[27]. The
gene expression level of HOXD9 in brain tumors was
compared to the expression in normal brain. Statistical
values calculated normalized data from MAS 5 algo-
rithm by the Wilcoxon signed rank test.
Bisulfate genomic sequencing
Genomic DNA was purified from each cell line using
the Wizard SV Genomic DNA Purification Kit (Pro-
mega, Madison, WI). T cells were isolated from periph-
eral blood mononuclear cells using magnetic beads
conjugated to anti-human CD3 (Miltenyi Biotech,
Tokyo, Japan). Bisulfate conversion was performed using
0.5-0.7 μg of genomic DNA and the reagents provided
in the Qiagen EpiTect Bisulfate kit (Qiagen). The con-
verted DNA was amplified by PCR using the following
primers: 5’-GAGGGGAGAATAGTTTTTTT-3’ and 5’-
CAAACCCAAATCCATATACCC-3’. The PCR products
were subcloned into the pGEM-T Easy vector (Promega)
and verified by sequencing.
Plasmid construction and transfection
pCMV6-XL5-HOXD9 containing a human full-length
cDNA was obtained from Origen Technologies, Inc
(Rockville, MD) and subcloned into a pMX-Ig vector
(gifted from Dr. T. Kitamura) to generate the pMX-
HOXD9. 293T and U87 cells were transfected with a
pMX-HOXD9 plasmid using FuGENE HD transfection
regent (Roche) according to the manufacturer’s protocol.
Western blot analysis
Cell lysates were prepared using the RIPA buffer (25
mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, and 0.1% SDS; pH 7.6) containing pro-
tease inhibitors (Cocktail Tablet; Roche Diagnostics,
Japan). Lysates were centrifuged at 14,000×g for 15 min
at 4°C, and the protein concentration of each sample
was determined with the Bio-Rad protein assay kit (Bio-
Rad, Hercules, CA) with bovine serum albumin as a
standard. Identical amounts of the proteins were elec-
trophoresed in 4-10% SDS-PAGE gels and transferred to
a nitrocellulose membrane. Blots were blocked with
Blocking One™ (Nacalai, Kyoto, Japan) at RT for 60
min, and incubated with either a goat anti-HOXD9 anti-
body (1:500; Santa Cruz Biotechnology. Inc, CA) and a
rabbit anti-GAPDH antibody (1:4,000; Santa Cruz Bio-
technology, Inc) overnight at 4°C. After being washed
three times in TBST (20 mM Tris-HCl, 150 mM NaCl,
and 0.02% tween-20; pH 7.4), the blots were incubated
with the secondary antibody conjugated with horserad-
ish peroxidase (1:4,000, anti-rabbit and anti-mouse;
Thermo Scientific, Tokyo) for 1 h at room temperature.
Signals were detected with a SuperSignal West Femto
Maximum Sensivity Subdstrate (Thermo Scientific) and
exposed to Hyperfilm (GE Health Care Biosciences).
The specificity of HOXD9 antibody was further con-
firmed by a peptide-absorption assay (Additional file 1,
Figure S1), in which the antibody was preincubated with
the corresponding peptide antigen by 1:5 weight ratio at
4°C and subjected to the analysis.
Small interfering RNA (siRNA) and transient transfection
siRNA duplexes were designed, synthesized, annealed,
and purified by RNAi Co., Ltd (Tokyo, Japan). The
sequences of the human HOXD9-specific siRNAs were
5’-GAGUUCGCCUCGUGUAGUUUU-3’ (HOXD9
siRNA-1) and 5’- CCACUACGGGAUUAAGCCUGA-3’
(HOXD9 siRNA-2). As a control, we used a non-silencing
siRNA with the sequence 5’-GUACCGCACGUCAUUC-
GUAUC-3’. U87 or SK-MG-1 SP cells (5-6 × 10
4 cells/
ml) were seeded in triplicate in tissue culture dishes (24-
well or 96-well) 24 h prior to siRNA transfection. Control
or HOXD9 siRNAs were transfected at a concentration of
50 nM using Lipofectamine RNAiMAX (Invitrogen)
according to the manufacturer’s instructions.
Cell proliferation assay
Following siRNA transfection, cells were harvested by
trypsinization and the total number of cells was counted
by trypan blue exclusion under a phase-contrast
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the Cell Titer-Glo Luminescent Cell Viability Assay kit
(Promega) according to the manufacturer’sp r o t o c o l ,
using a luminometer (Wallac ARVO 1420 multilabel
counter; WALLAC OY, Truku, Finland). Cell cycle ana-
lysis for live cells was performed using flow cytometry.
siRNA-treated cells were stained with Vybrant DyeCycle
Violet Stain (Invitrogen) for 30 min at 37°C according
to the manufacturer’s protocol and then subjected to
flow cytometry (Gallios; Beckman Coulter). Raw data
were analyzed using Multicycle for Windows (Beckman
Coulter).
Colony formation assay
48 h after siRNA transfection, cells (2 × 10
4 cells) were
mixed with 2 ml of culture medium containing 0.4%
agar and 10% FCS and then plated on 2 ml of the bot-
tom layer containing 0.6% agar with 10% FCS in each
well of a 6-well plate. Each experiment was performed
in triplicate. After 3 weeks culture, colonies were
counted after staining with MTT 3-(4,5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H-tetrazolium bromide.
Apoptosis assay
Caspase 3/7 activity in siRNA-transfected cells was mea-
sured using the Caspase-Glo 3/7 assay kit (Promega)
according to the manufacturer’s instructions. U87 cells
were plated in 96-well plates at a seeding density of 6 ×
10
3 cells/well, and caspase activity was assayed 48 h
after siRNA transfection. To differentiate between apop-
totic and necrotic cell death, siRNA-transfected cells (1
×1 0
5 cells/ml) were stained with 5 μl Annexin-V anti-
body and 5 μl 7-AAD using an Annexin V-FITC/7-
AAD-staining kit (Beckman Coulter), placed on ice for
10 min in the dark, and then analyzed by flow cytome-
try(EPICS XL; Beckman Coulter).
Time-lapse cell imaging
Cells were transfected with control siRNA, HOXD9
siRNA-1 and HOXD9 siRNA-2. 24 h after transfection,
10,000 cells were plated on 24-well glass plates (IWAKI,
Tokyo, Japan) and imaged using a NIKON TE2000-E
microscope equipped with ×200 magnification lens
(Nikon, Tokyo, Japan). The microscope stage was
enclosed by a plastic air curtain and heated to 37°C.
Time-lapse recordings were taken every 5 minutes for
96 h and analyzed using the image analysis software
MetaMorph (Molecular Devices, Downingtown, PA).
The cell division time of cells transfected with siRNAs
was determined using the time-lapse images.
Immunohistochemical staining
Paraffin-embedded tissue sections (5 μm) were deparaffi-
nized in xylene and rehydrated. The sections were treated
with a heat-based antigen retrieval method using a citrate
solution (pH 6.0, 10 mM). Nonspecific binding of antibo-
dies was blocked by incubation in 5% rabbit serum in
0.01 M PBS for 30 min. The slides were then incubated
with goat anti-human HOXD9 polyclonal antibody
(1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
diluted with 0.02% BSA in 0.01 M PBS overnight at 4°C
in a humidified box. The slides were then incubated with
a secondary antibody (Universal Immuno-peroxidase
Polymer, Anti-goat; Histofine Simple Stain MAX PO (G),
Nichirei Corporation, Tokyo, Japan) for 30 min at 37°C,
and horseradish peroxidase labeling was visualized using
3,3’-diamonobenzidene (DAB). The sections were then
lightly counterstained with hematoxylin. Each step was
followed by three washes in PBS. To evaluate the prolif-
eration of tumor cells, the same sections were stained
with the monoclonal antibody MIB-1 (1:200; DAKO
Japan, Kyoto, Japan) that recognizes the Ki-67 protein.
The proliferating cell indexes were analyzed for >1000
tumor cells in more than three areas expressing the high-
est number of immunopositive nuclei. The analysis was
performed using a digital camera (DXM-1200) attached
to a microscope (Nikon) and ACT-1 software (Nikon).
Immunohistochemical staining was performed in 29
glioma cases (5 diffuse astrocytomas, 11 anaplastic astro-
cytomas and 13 glioblastomas).
Statistical analysis
The results are presented as mean values ± S.D. Data
were analyzed using a Student’s t test with P < 0.05 con-
sidered statistically significant.
Results
Analysis of HOXD9 gene expression in gliomas
To examine the expression level of HOXD9 mRNA in tis-
sues, we firstly performed qRT-PCR analysis in normal
human tissues using intron-spanning gene-specific pri-
mers. HOXD9 was highly expressed in normal colon,
spleen, kidney, testis, placenta, and bladder but poorly in
the brain (Figure 1A). Next, we performed qRT-PCR ana-
lysis in glioma tissues obtained from our university hos-
pital, all seven samples showed a >9-fold higher
expression as compared with both normal fetal and adult
brain samples (Figure 1B). This led us to investigate
HOXD9 expression throught the published microarray
databases. Bioinformatic analysis of data collected from
published transcriptomes suggests an increase of HOXD9
expression in gliomas and more particularly in glioblasto-
mas as compared to the normal brain tissues and medul-
loblastomas. Considering the heterogeneity of the
samples and methods used, a statistical analysis of these
differences was not relevant in these data sets (Figure
1C). However, focusing on a given study was more infor-
mative. As per the example of Sun et al 2006 we observe
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Page 4 of 14Figure 1 HOXD9 expression in gliomas. (A) Analysis of HOXD9 gene expression in human normal tissues by qRT-PCR. (B) Analysis of HOXD9
gene expression in gliomas (diffuse astrocytoma [DA], anaplastic astrocytoma [AA], and glioblastoma multiform [GBM]) by qRT-PCR. (A), (B), Data
were normalized using the results raised with the normal adult brain as reference. The graphs show the average of two independent
experiments. Error bars indicate ± S.D. (C) Expression levels of HOXD9 in normal brain and brain tumors. Data were normalized using the results
raised with the normal brain as reference. Gene expression and clinical outcome data were obtained from Gene Expression Omnibus (GEO) data
sets at NCBI (GSE3526, GSE10327, GDS1962). (D) Analysis of HOXD9 gene expression in glioma cells and normal human astrocytes (NHA). For the
graphs, the data are complied from three independent experiments. Error bars indicate ± S.D.
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examined the expression of HOXD9 mRNA in four
glioma cell lines, U87, SK-MG-1, KNS-42 and KNS-81
and found higher expression of HOXD9 mRNA com-
pared with that in normal human astrocytes (33-, 32.5-,
52.8-, and 57.5-fold higher, respectively; Figure 1D).
Immunohistochemical analysis of HOXD9 in gliomas
Immunohistochemical analysis showed that the number
of HOXD9-positive cells was very low in normal cere-
bral cortex tissue surrounding a surgical biopsy, in
agreement with our results from qRT-PCR (Figure 1C
and 2A). However, HOXD9-positive cells were observed
in both anaplastic astrocytoma (Figure 2B) and GBM
tissues (Figure 2C). To examine the antibody specificity,
no primary antibody staining was performed (Figure
2D). Furthermore, immunizing peptide adsorption
experiments by western blot method (Additional file 1,
Figure S1) and immunohistochemical method in kidney
tissues (data not shown) showed that weak immunor-
eactivity, confirming the specificity of the antibody.
In some cells, HOXD9 immunoreactivity was observed
in the both cytoplasm and the nucleus (Figure 2B); how-
ever, most of the HOXD9 labeling was confined to the
nucleus, consistent with its function as a transcription
factor (Figure 2C). We also observed no correlation
between HOXD9 expression and cell proliferation in
gliomas using the MIB-1 index (Table 1).
Gene silencing of HOXD9 decreases cell proliferation of
glioma U87 cells
To investigate the role of HOXD9 in tumor cells, we
examined changes in U87 glioma cell proliferation in
the absence of HOXD9 using siRNA. We designed two
different siRNAs to reduce the gene expression of
HOXD9 (Figure 3A). Cell number was counted 2 and 4
days after siRNA transfection into U87 cells. There were
fewer cells present after transfection with either of the
two HOXD9 siRNAs compared with the control siRNA
transfected cells (Figure 3B). In addition, the decrease of
cell proliferation by HOXD9 gene silencing was observed
in KNS-42 and KNS-81 glioma cells (Additional file 2,
Figure 2 Immunohistochemical analysis of HOXD9 expression in gliomas and normal brain tissue. Only a few HOXD9 immunopositive
cells were detected in normal tissues from the cerebral cortex in an oligodendroglioma (A). In an anaplastic astrocytoma (B, WHO grade III) and
a glioblastoma (C, WHO grade IV), HOXD9 immunopositive cells were observed in both the cytoplasm and the nucleus. (D) No primary antibody
control. The sections were counterstained with hematoxylin. The boxed area shows higher magnification images. Scale bar = 25 μm.
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DyeCycle Violet dye showed that the S-phase and G2-
phase cell populations decreased 3 days after HOXD9
siRNA transfection in U87 cells (Figure 3C). Further-
more, gene silencing of HOXD9 reduced the number of
colony formation in U87 glioma cells compared to the
control (Figure 3D). These results suggest that HOXD9
may be involved in glioma cell proliferation.
Gene silencing of HOXD9 induces apoptosis in U87
glioma cells
In addition to the analysis of proliferation, we analyzed the
effect of HOXD9 gene silencing on apoptosis in U87 cells.
We evaluated the cell division time and morphological
changes in U87 glioma cells after HOXD9 siRNA trans-
fection using a time-lapse video microscope system
according to our previous study[29]. The average cell
division time in HOXD9 siRNA-transfected cells was
greater than that in the control cells (47.2 ± 18 h for
control siRNA vs. 81.1 ± 1.3 h for HOXD9 siRNA-2, p =
0.03; Figure 4A). Furthermore, many HOXD9 cells
underwent apoptosis, observed as cell fragmentation (Fig-
ure 4B). To confirm whether the morphological changes
were the result of apoptotic cell death, we performed
flow cytometric analysis using Annexin-V/7-ADD stain-
ing. Compared with control cells, the number of Annexin
V
+/7-ADD
- cells was significantly higher after HOXD9
siRNA transfection on Day 3 (Figure 4C). The total
Table 1 Association of HOXD9 expression and MIB-1 index in glioma tissues
Case no Histology Age (years) Sex MIB-1(%)
a Immunohistochemistry
b
WHO grade IV
GB1 Glioblastoma 60 M 40.7 +++
GB2 Glioblastoma 79 F 44.8 +++
GB3 Glioblastoma 72 M 9.1 +
GB4 Glioblastoma 55 F 14.0 +
GB5 Glioblastoma 34 M 8.0 +
GB6 Glioblastoma 28 M 53.0 +++
GB7 Glioblastoma 33 M 8.1 ++
GB8 Glioblastoma 55 F 37.2 +++
GB9 Glioblastoma 69 M 30.1 ++
GB10 Glioblastoma 38 M 36.4 +
GB11 Glioblastoma 61 F 23.8 +
GB12 Glioblastoma 53 F 11.2 +
GB13 Glioblastoma 60 F 20.4 +
WHO grade III
AA1 Anaplastic astrocytoma 50 F 0.8 +++
AA2 Anaplastic astrocytoma 77 F 2.6 +
AA3 Anaplastic astrocytoma 36 M 1.2 ++
AA4 Anaplastic astrocytoma 76 F 34.2 +
AA5 Anaplastic astrocytoma 39 M 2.2 ++
AA6 Anaplastic astrocytoma 27 M 5.2 +
AA7 Anaplastic astrocytoma 52 F 19.6 +++
AA8 Anaplastic astrocytoma 45 F 4.0
AA9 Anaplastic astrocytoma 27 F 7.8 -
AA10 Anaplastic astrocytoma 39 F 3.2 +++
AA11 Anaplastic astrocytoma 9 F 1.6 +
WHO grade II
DA1 Diffuse astrocytoma 37 M 4.5 +
DA2 Diffuse astrocytoma 36 M 3.0 ++
DA3 Diffuse astrocytoma 3 M 2.9 ++
DA4 Diffuse astrocytoma 50 M 1.
DA5 Diffuse astrocytoma 10 M 2.4 ++
a The proliferating cell index was analyzed in >1000 tumor cells in more than three areas expressing the highest number of MIB-1-positive nuclei.
b The patterns
of HOXD9 staining are described as (-) negative or faint staining; (+) positive in less than 30% of tumor cells; (++) positive in less than 70% of tumor cells; (+++)
positive in more than 70% of tumor cells. M, male; F, female.
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+ cells was higher after HOXD9
siRNA transfection (Figure 4D). We also measured the
activity of caspase 3/7, which is known to promote apop-
tosis. Two days after HOXD9 siRNA transfection, caspase
3/7 activity was induced (Figure 4E).
To identify the molecules involved in cell death asso-
ciated with HOXD9 silencing, we extracted total RNA
from control- and HOXD9-siRNA transfected cells on
Day 2, and subjected them to DNA microarray analysis.
Genes that showed a >2-fold change in expression
Figure 3 Silencing of HOXD9 gene decreases proliferation of U87 glioma cells. (A) Analysis of HOXD9 gene expression by qRT-PCR 2 days
after siRNA transfection. The graphs show the average of two independent experiments. For the graphs, the data are complied from three
independent experiments. * *, P < 0.01. Error bars indicate ± S.D. (B) Growth suppression of U87 glioma cells after HOXD9 siRNA transfection.
siRNA-transfected cells were counted by trypan blue exclusion. Data are representative of three independent experiments. *, P < 0.05. Error bars
indicate ± S.D. (C) Cell cycle alteration by HOXD9 siRNA-1 in U87 glioma cells 3 days after siRNA treatment. Results of flow cytometry analysis
using Vybrant DyeCycle Violet dye are shown. Data are representative of three independent experiments. (D) 3 weeks after siRNA transfection,
colonies stained with MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] were counted. For the graphs, the data are complied
from three independent experiments. *, P < 0.05. Error bars indicate ± S.D.
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Page 8 of 14Figure 4 Silencing of HOXD9 gene induces apoptosis in U87 glioma cells. (A) Average cell division time of siRNA-treated cells was
measured for 4 days starting 24 h after transfection (n = 3). *, P < 0.05. Error bars indicate ± S.D. (B) Representative images of U87 glioma cells
transfected with control or HOXD9 siRNA in the time-laps cell imaging analysis of three independent experiments (C) Determination of apoptosis
by flow cytometry 3 days after siRNA transfection. Early apoptosis (lower right, Annexin V
+/7ADD
-), late apoptosis (upper right, Annexin V
-/7ADD
+), necrotic cells (upper left, Annexin V
-/7ADD
+), and normal cells (lower left, Annexin V
-/7-ADD
-) from a representative experiment at least three
independent experiments. (D) Average percentage of Annexin V
+ cells. For the graphs, the data are complied from three independent
experiments. **, P < 0.01. Error bars indicate ± S.D. (E) Analysis of caspase3/7 activity in U87 glioma cells 48 hr after siRNA treatment. For the
graphs, the data are complied from three independent experiments. *, P < 0.05, **, P < 0.01. Error bars indicate ± S.D.
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Page 9 of 14between control siRNA- and HOXD9 siRNA-transfected
cells were considered to be significantly changed. Figure
5A shows the cluster analysis of selected genes obtained
from the Gene Ontology database under the classifica-
tions “apoptosis regulator activity” and “cell growth and/
or maintenance”. Of the listed genes, we focused on
BCL-2, a known anti-apoptotic factor, and TRAIL,a
member of the tumor necrosis factor family of cell
death-inducing ligands, as candidate apoptosis-related
genes in this study. It has been reported that TRAIL can
induce apoptosis in U87 cells[30]. To confirm the
results from the microarray analysis, we performed
qRT-PCR analysis to quantify the mRNA level of these
two genes. Compared with control siRNA-transfected
U87 cells, BCL-2 mRNA was lower and TRAIL mRNA
was higher in HOXD9 siRNA treated cells, consistent
with the results from the microarray analysis (Figure
5B). Collectively, these results suggest that HOXD9
silencing promotes cell death in U87 cells.
HOXD9 is involved in the proliferation of SK-MG-1 SP cells
Recently, we found that a side population (SP) of cells in
a glioma cell line, SK-MG-1, possesses the properties of
glioma stem-like cells[22]. We analyzed the expression
levels of HOXD9 in SP and non-SP SK-MG-1 cells
using qRT-PCR, and found higher expression of
HOXD9 mRNA in SP cells compared with non-SP cells
(Figure 6A). We performed a cell proliferation assay
using SP cells transfected with either control or HOXD9
siRNA. QRT-PCR confirmed efficient gene silencing of
HOXD9 in SK-MG-1 SP cells transfected with HOXD9
siRNA (data not shown). The viability of SK-MG-1 SP
cells was significantly attenuated by HOXD9 siRNA
compared with control siRNA 48 h after transfection
(Figure 6B).
HOXD9 expression in human GCSCs
We cultured human GCSCs as glioma spheres from
glioma surgical specimens and established five cell lines
as described in our previous study[10]. SOX2,ak n o w n
neural stem/progenitor cell (NSPC) marker, is also
expressed in gliomas and GCSCs[31]. We performed
qRT-PCR to examine the expression of HOXD9 and
SOX2 in GCSCs compared with normal primary astro-
cytes and NSPCs derived from fetal brain and cultured as
neurospheres[32]. The expression of SOX2 and HOXD9
in GCSCs was higher than that in normal astrocytes and
NSPCs. Also, HOXD9 expression was higher than SOX2
expression in some GCSCs (Figure 6C).
Discussion
This is the first study examining the function of HOXD9
in gliomas. We found that HOXD9 was more highly
expressed in gliomas and GCSCs and that gene silencing
of HOXD9 reduced the proliferation of both glioma cells
and glioma cancer stem-like cell population.
The expression of homeobox family genes is generally
restricted during embryogenesis. Recently, it was reported
that HOXD9 is expressed in murine neural tubes and
neural crest cells during development[33]. In this study,
we observed the high expression of HOXD9 in normal
adult human kidney and testis. The misexpression of
homeobox transcription factor genes has also been
reported in cancer tissues; for example, HOXA1 and Six1
transform mammary epithelial cells[34,35], and Msx1 and
Cdx transform myoblasts[36] and intestinal epithelial cells
[37], respectively. Although the mechanisms underlying
the misexpression of homeobox transcription factor genes
in cancer remain elusive, the deregulation of non-coding
RNA expression and/or changes in the methylation status
of the promoters may be involved. Recently, it has been
reported that non-coding RNA residing in the HOXC
locus could act in trans to regulate transcription of the
HOXD locus with the Polycomb-repressive complex 2
(PRC2)[38]. HOXD11 and HOXD12 are regulated by the
Polycomb group proteins during embryonic stem cell dif-
ferentiation[39]. We performed bisulfate sequencing to
compare the methylation status of the HOXD9 promoter
in U87 cells compared with normal human T cells and
NSPCs. Hypermethylation of CpG islands was observed in
the HOXD9 promoter region in U87 cells compared to T
cells and NSPCs when HOXD9 gene expression was high
(Additional file 3, Figure S3). This relationship between
gene expression and methylation status has also been
observed in HOXB family genes in small-cell lung cancer
[40]. Hypermethylation of CpG islands in promoter
regions has been reported for many genes, including the
HOXC and HOXD cluster genes associated with HOXD9
in human astrocytomas[39,41]. It is difficult to understand
why hypermethylation correlates with increased rather
than decreased gene expression. In the future, it may be
important to evaluate the methylation status of HOXD9 in
the whole genome, as well as histone modification in glio-
mas and GCSCs compared with normal brain and NSPCs
using the tiling array system and/or a next-generation
sequencer. Thus, the analyses of epigenetic regulation of
HOXD9 gene expression in gliomas and GCSCs related to
Polycomb proteins and non-coding RNA will be an impor-
tant issue in the near future.
We showed that gene knockdown of HOXD9 reduces
the proliferation of U87, KNS-42, and KNS-81 glioma
cells and glioma cancer stem-like cells; SK-MG-1 SP
cells. So far, HOXD9 is reported to be involved in the
regulation of cell proliferation in rheumatoid arthritis
[42] and carcinogenesis[43], indicating that HOXD9 may
contribute to cell proliferation in HOXD9-expressing
cells in gliomas including GCSCs In our preliminary
experiment, transiently over-expressed HOXD9
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Page 10 of 14Figure 5 Effect of HOXD9 gene knockdown on the expression of apoptosis- and cell proliferation-related factors. (A) Gene expression in
U87 glioma cells transfected with HOXD9 siRNA or control siRNA was determined by microarray analysis. A gene list generated by a Gene
Ontology search against “Apoptosis regulator activity” and “Cell growth and/or maintenance” was clustered using a hierarchical method. The red,
green, and brown scale represents the expression level of a gene above, below, or equal to the mean expression level for that gene across all
samples, respectively. (-) indicates that the gene was not annotated in the NCBI gene bank list. (B) Analysis of BCL-2 and TRAIL gene expression
in U87 glioma cells by qRT-PCR 2 days (BCL-2) or 3 days (TRAIL) after siRNAs transfection. Each mRNA was normalized against GAPDH mRNA and
expressed relative to the normalized value for control siRNA-treated cells. For the graphs, the data are complied from three independent
experiments. **, P < 0.01. Error bars indicate ± S.D.
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Page 11 of 14Figure 6 Analysis of the expression and function of HOXD9 in glioma cancer stem cells. (A) Analysis of HOXD9 gene expression in SK-MG-
1 SP cells, SK-MG-1 non-SP cells, and total SK-MG-1 glioma cells. The abundance of HOXD9 mRNA was normalized to that of GAPDH mRNA and
expressed relative to the normalized value for SK-MG-1 cells. For the graphs, the data are complied from three independent experiments. Error
bar indicates mean ± S.D. (B) Gene knockdown of HOXD9 in SK-MG-1 SP cells attenuated cell proliferation. Cell viability was determined 2 days
after siRNA treatment. The experiment was repeated twice, with similar results. *, P < 0.05. Error bars indicate ± S.D. (C) Expression of the HOXD9
and SOX2 genes was examined by qRT-PCR in normal human astrocytes (NHA), human NSPCs, and GCSCs cultured from glioma surgical biopsy
specimens. The abundance of HOXD9 and SOX2 mRNA was normalized to that of GAPDH and expressed relative to the normalized value for
NHA. Data shown are the mean ± S.D. from two independent experiments.
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Page 12 of 14increased the S-phase cell population of U87 cells in cell
cycle analysis (data not shown). In this study, gene silen-
cing of HOXD9 induced apoptosis and reduced the
expression of BCL-2 in glioma cells, indicating that
HOXD9 may support the cell survival. Furthermore,
immunohistochemical studies showed no apparent cor-
relation between HOXD9 expression level and WHO
grade or MIB-1 index, suggesting that HOXD9 may be
expressed in primitive cancer cell populations, including
GCSCs in vivo. As for the upstream factors of HOXD9,
it has been reported that HOXD9 expression is induced
by Wnt signaling[33], which is a maintenance factor for
neural stem cells[44] and neural crest cells[45], suggest-
ing that HOXD9 may act as a maintenance or survival
factor for GCSCs undercontrol of Wnt signaling.
HOXB1 also supports the maintenance and expansion of
neural progenitor cells[46], and HOXB4 may expand
hematopoietic stem cells[47]. Taken together, these
results indicate that some homeobox proteins including
HOXD9 may contribute to cancer stem cell maintenance
in addition to the cell proliferation and/or survival.
In the present study, we demonstrated that HOXD9
was highly expressed in glioma cells and GCSCs cultured
from patient specimens compared with human NSPCs
and astrocytes. To date, drug development for targeting
cancer stem cells is an important issue in cancer therapy
[48]. Therefore, it is very important for this purpose to
find targets expressed in cancer stem cells with a high
specificity. In this point, HOXD9 may be an ideal thera-
peutic target for the treatment of gliomas because the
expression in NSPCs and astrocytes is lower than
GCSCs, suggesting that HOXD9 targeted therapy may
have a therapeutic index. In fact, knockdown of HOXD9
decreased the proliferation of glioma cancer stem-like
cells in vitro, supporting the idea. Recently, it has been
reported that HOXA9 decreases apoptosis and increases
cell proliferation in glioma cells by epigenetic control[49]
and the expression of HOXA10 in GBM-derived spheres
[50]. Thus, it may be intriguing to study the detailed ana-
lysis of HOX families in GCSCs in the future for the
development of drug discovery targeted for GCSCs.
Conclusions
HOXD9 m a yb eu s e f u la sam a r k e rf o rg l i o m aa n d
GCSCs, and therapies targeting HOXD9 should be con-
sidered for further development.
Additional material
Additional file 1: Figure S1. Peptide pre-absorption analysis of
Western blot. The anti-HOXD9 antibody was pre-incubated with
blocking peptide (antigen) by 1:5 Weight ratio at 4°C overnight.
Immunizing peptide adsorption showed weak immunoreactivity towards
over-expressed HOXD9 in 293T cells.
Additional file 2: Figure S2. Silencing of HOXD9 gene decreases
proliferation of KNS-42 and KNS-81 glioma cells. (A) Analysis of
HOXD9 gene expression by qRT-PCR analysis 2 days after siRNA
transfection in KNS-42 and KNS-81 glioma cells. (B) Gene knockdown of
HOXD9 in in KNS-42 and KNS-81cells attenuated cell proliferation. Cell
viability was determined 2 days after siRNA treatment. For the graphs,
the data are complied from three independent experiments. *, P < 0.05,
**, P < 0.01. Error bars indicate ± S.D.
Additional file 3: Figure S3. Analysis of CpG methylation. (A) A
schematic representation of the previously described restriction landmark
genomic scanning (RLGS) clone[16] and the position of the CpG islands
within the promoter region of the HOXD9 gene. (B) Methylation maps
derived from bisulfate sequencing analysis of human T cells, NSPCs, and
U87 glioma cells. ●, methylated; ○, unmethylated.
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